NBS System for MDD
Major Depressive Disorder
ApprovedActive
Key Facts
About Nexstim
Nexstim is a commercial-stage medical device company with a unique focus on navigated Transcranial Magnetic Stimulation (nTMS). Its proprietary SmartFocus® technology platform integrates patient-specific MRI data with a multi-sphere head model to visualize and navigate the induced electric field (E-field) in the brain in real-time, enabling unprecedented targeting accuracy. The company's NBS systems are used for pre-surgical mapping in neurosurgery and for therapeutic treatment of conditions like depression and obsessive-compulsive disorder (OCD). As a publicly traded company, Nexstim is expanding its commercial footprint and regulatory clearances for its latest NBS System 6.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Neurotyping Platform for MDD | Universal Brain | Development |
| CLE-100 | Clexio Biosciences | Phase 2 |
| Proliv™Rx | Neurolief | Phase 2 |